PAX transcriptional network is interrupted by AZD5153 and acalabrutinib in TMD8 tumor models. RNA-sequencing data generated from tumors extracted after 4 hours of drug dosing, n = 3 mice per group. (A) Venn diagram of genes with significant differential expression between treatment and vehicle. (B-C) Log fold-change (LFC) values for combination differential expression (x-axis) compared with (B) 0.72 mg/kg AZD5153 or C 20 mg/kg acalabrutinib (y-axis). All the genes were significant (P < .05) after at least 1 treatment and a 1.5-fold–change threshold was applied. (D-E) Pathway analysis of 514 differentially expressed genes exclusive of the combination treatment. (D) GO Biological and (E) Perturbed Transcription Factors databases. Statistical P values < 0.05 were considered significant.